New agents targeting angiogenesis in glioblastoma.

about

Unique biology of gliomas: challenges and opportunities.VEGFR-2 Expression in Glioblastoma Multiforme Depends on Inflammatory Tumor Microenvironment.Impact of Blood Vessel Quantity and Vascular Expression of CD133 and ICAM-1 on Survival of Glioblastoma Patients.

P2860

Q36626214-73266724-E2F3-4AC4-A99D-999B2B3D2015 Q41857963-B6DD5C3C-7E8A-4D24-9E09-E38FD5C3C47F Q47122277-399FE61C-6CE8-429F-927A-819DB5B57961

P2860

New agents targeting angiogenesis in glioblastoma.

Item

http://www.wikidata.org/entity/Q39657781

description

2011 nî lūn-bûn

@nan

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

2011年论文

@zh

2011年论文

@zh-cn

name

New agents targeting angiogenesis in glioblastoma.

@en

New agents targeting angiogenesis in glioblastoma.

@nl

type

Item

label

New agents targeting angiogenesis in glioblastoma.

@en

New agents targeting angiogenesis in glioblastoma.

@nl

prefLabel

New agents targeting angiogenesis in glioblastoma.

@en

New agents targeting angiogenesis in glioblastoma.

@nl

P1476

New agents targeting angiogenesis in glioblastoma.

@en

P2093

Eleni Timotheadou

http://www.w3.org/2001/XMLSchema#string

P2860

VEGF-Trap: a VEGF blocker with potent antitumor effects.

Diversity of function is inherent in matricellular proteins: an appraisal of thrombospondin 1

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

Nanomolar small molecule inhibitors for alphav(beta)6, alphav(beta)5, and alphav(beta)3 integrins

Thrombospondin 1 and type I repeat peptides of thrombospondin 1 specifically induce apoptosis of endothelial cells

AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer

Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy

The role of myeloid cells in the promotion of tumour angiogenesis

Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma

A phase 2 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: a North American Brain Tumor Consortium study.

P304

878912

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1155/2011/878912

http://www.w3.org/2001/XMLSchema#string

P478

2011

http://www.w3.org/2001/XMLSchema#string

P577

2011-11-02T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

221796374

http://www.w3.org/2001/XMLSchema#string

P698

22295207

http://www.w3.org/2001/XMLSchema#string

P932

3263613

http://www.w3.org/2001/XMLSchema#string

New agents targeting angiogenesis in glioblastoma.

about

P2860

P2860

New agents targeting angiogenesis in glioblastoma.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P478

P577

P5875

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P478

P577

P5875

P698

P932